YvetteLeslieKasamonMD

Hematologic Oncology

Physician, Division of Hematologic Malignancies II, Office of Oncologic Diseases, FDA and Adjunct Associate Professor of Oncology, Johns Hopkins University School of Medicine

Join to view full profile

Dr. Kasamon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kasamon's full profile

Already have an account?

Office
FDA, 10933 New Hampshire Ave
White Oak 22/ 2163
Silver Spring, MD 20903
Phone+1 240-402-3694
Is this information wrong?

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2002 - 2005
Brigham and Women's HospitalResidency, Internal Medicine, 1999 - 2002
University of Pittsburgh School of MedicineClass of 1999

Certifications & Licensure

MD State Medical License 2002 - 2024
American Board of Internal Medicine Hematology

Clinical Trials

Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma Start of enrollment: 2005 Nov 01
Completed
Phase 1, Phase 2
Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2006 Aug 01
Withdrawn
Phase 2
Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies Start of enrollment: 2006 Oct 01
Terminated
Phase 1
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma Start of enrollment: 2006 May 01
Completed
Phase 2
Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma Start of enrollment: 2007 Apr 01
Terminated
Phase 1, Phase 2
Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma Start of enrollment: 2007 Jun 01
Completed
Phase 1, Phase 2
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma Start of enrollment: 2007 Nov 01
Completed
Phase 1
Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab Start of enrollment: 2009 Jul 01
Terminated
Phase 2
124I-FIAU Imaging in EBV and KSHV Associated Cancers Start of enrollment: 2010 Dec 01
Completed
Not Applicable
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers Start of enrollment: 2010 Aug 01
Terminated
Phase 2
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Start of enrollment: 2010 Sep 01
Recruiting
Phase 1, Phase 2
Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide Start of enrollment: 2011 Apr 01
Terminated
Phase 2
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide Start of enrollment: 2011 Aug 01
Completed
Phase 1
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma Start of enrollment: 2014 Jun 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma.
Peredo-Pinto, H., Wang, C., Xu, Z., Tegenge, M., Elmacken, M., Jaigirdar, A., Theoret, M., Purohit-Sheth, T., Kasamon, Y.> ;Clinical Cancer Research. 2024 Feb 7
1 citations
FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma.
Deepti Telaraja, Yvette L Kasamon, Justin S Collazo, Ruby Leong, Kun Wang, Ping Li, Elyes Dahmane, Yuching Yang, Justin Earp, Manuela Grimstein, Lisa R Rodriguez, Marc...> ;Clinical Cancer Research. 2024 Jan 5
3 citations
FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma.
Poornima Sharma, Yvette L Kasamon, Xue Lin, Zhenzhen Xu, Marc R Theoret, Tejashri Purohit-Sheth> ;Clinical Cancer Research. 2023 Nov 1
13 citations
Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival.
Margret Merino, Yvette Kasamon, Marc Theoret, Richard Pazdur, Paul Kluetz, Nicole Gormley> ;Journal of Clinical Oncology. 2023 May 20
Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective.
Andrea C Baines, Maryam Sarraf Yazdy, Yvette L Kasamon, Rachel Ershler, Emily Y Jen, Bindu Kanapuru, Nicholas C Richardson, Ashley Lane, Theresa Carioti, Marc R Theore...> ;Clinical Cancer Research. 2023 Aug 1
16 citations
FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Margret Merino, Yvette Kasamon, Hongshan Li, Lian Ma, Ruby Leong, Jiaxi Zhou, Gregory Reaman, Wiley Chambers, Nicholas Richardson, Marc Theoret, Richard Pazdur, Nicole...> ;Pediatric Blood & Cancer. 2022 Aug 1
34 citations
The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint.
Nicholas C Richardson, Yvette Kasamon, Richard Pazdur, Nicole Gormley> ;The Lancet. Oncology. 2022 May 1
3 citations
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma.
Najat Bouchkouj, Megan Zimmerman, Yvette L Kasamon, Cong Wang, Tianjiao Dai, Zhenzhen Xu, Xiaofei Wang, Marc Theoret, Tejashri Purohit-Sheth, Bindu George> ;The Oncologist. 2022 Jul 5
43 citations
HLA Informs Risk Predictions after Haploidentical Stem Cell Transplantation with Post-transplantation Cyclophosphamide.
Ephraim J. Fuchs, Shannon R. McCurdy, Scott R. Solomon, Tao Wang, Megan M. Herr, Dipenkumar Modi, Michael R. Grunwald, Taiga Nishihori, Michelle Kuxhausen, Stephanie F...> ;Blood. 2021 Nov 1
15 citations
FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Yvette L. Kasamon, Lauren S. L. Price, Olanrewaju O. Okusanya, Nicholas C. Richardson, Ruo-Jing Li, Lian Ma, Yu-Te Wu, Marc R. Theoret, Richard Pazdur, Nicole J. Gormley> ;The Oncologist. 2021 Oct 1
151 citations
Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement.
Aaron Orkin, Peter J Gill, Davina Ghersi, Lisa Campbell, Jeremy Sugarman, Richard Emsley, Philippe Gabriel Steg, Charles Weijer, John Simes, Tanja Rombey, Hywel C Will...> ;JAMA. 2021 Jan 1
7 citations
Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study.
Christine M. Durand, Adam A. Capoferri, Andrew D. Redd, Marianna Zahurak, Daniel I. S. Rosenbloom, Ayla Cash, Robin K. Avery, Javier Bolaños-Meade, Catherine M. Bollar...> ;The Lancet. HIV. 2020 Sep 1
35 citations
FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome.
Yvette L. Kasamon, Haiyan Chen, R. Angelo de Claro, Lei Nie, Jingjing Ye, Gideon M. Blumenthal, Ann T. Farrell, Richard Pazdur> ;Clinical Cancer Research. 2019 Dec 15
41 citations
FDA Approval Summary: Brentuximab Vedotin in First‐Line Treatment of Peripheral T‐Cell Lymphoma
Nicholas C. Richardson, Yvette L. Kasamon, Haiyan Chen, R. Angelo de Claro, Jingjing Ye, Gideon M. Blumenthal, Ann T. Farrell, Richard Pazdur> ;The Oncologist. 2019 May 1
11 citations
ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.
Paolo Strati, Michelle A. Fanale, Yasuhiro Oki, Francesco Turturro, Luis Fayad, Nancy L. Bartlett, Douglas E. Gladstone, Yvette L. Kasamon, Carol S. Portlock, Wyndham ...> ;Haematologica. 2019 Feb 1
27 citations
FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
Yvette L. Kasamon, Chia-Wen Ko, Sriram Subramaniam, Lian Ma, Yuching Yang, Lei Nie, Stacy S. Shord, Donna Przepiorka, Ann T. Farrell, Amy E. McKee, Richard Pazdur> ;The Oncologist. 2018 Dec 1
140 citations
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
Najat Bouchkouj, Yvette L. Kasamon, R. Angelo de Claro, Bindu George, Xue Lin, Shiowjen Lee, Gideon M. Blumenthal, Wilson Bryan, Amy E. McKee, Richard Pazdur> ;Clinical Cancer Research. 2019 Mar 15
54 citations
Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors
Hany Elmariah, Yvette L. Kasamon, Marianna Zahurak, Karen W. Macfarlane, Noah Tucker, Gary L. Rosner, Javier Bolaños-Meade, Ephraim J. Fuchs, Nina Wagner-Johnston, Lod...> ;Biology of Blood and Marrow Transplantation. 2018 May 1
25 citations
Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation
Yvette L. Kasamon, Ephraim J. Fuchs, Marianna Zahurak, Gary L. Rosner, Heather J. Symons, Douglas E. Gladstone, Carol Ann Huff, Lode J. Swinnen, Robert A. Brodsky, Wil...> ;Biology of Blood and Marrow Transplantation. 2018 May 1
7 citations
Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients.
Tara M. Robinson, Gabrielle T. Prince, Christopher J. Thoburn, Erica D. Warlick, Anna Ferguson, Yvette L. Kasamon, Ivan Borrello, Allan D. Hess, B. Douglas Smith> ;Leukemia & Lymphoma. 2018 Apr 4
54 citations
Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplan...
Shannon R. McCurdy, Christopher G. Kanakry, Hua Ling Tsai, Yvette L. Kasamon, Margaret M. Showel, Javier Bolaños-Meade, Carol Ann Huff, Ivan Borrello, William Matsui, ...> ;Biology of Blood and Marrow Transplantation. 2018 Feb 1
8 citations
Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma
Heather A. Jacene, John Crandall, Yvette L. Kasamon, Richard F. Ambinder, Steven Piantadosi, Donna Serena, Wayne Kasecamp, Richard L. Wahl> ;Molecular Imaging and Biology. 2017 Jun 1
106 citations
FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma
Yvette L. Kasamon, R. Angelo de Claro, Yaping Wang, Yuan Li Shen, Ann T. Farrell, Richard Pazdur> ;The Oncologist. 2017 May 1
61 citations
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.
Christopher G. Kanakry, Javier Bolaños-Meade, Yvette L. Kasamon, Marianna Zahurak, Nadira Duraković, Terry Furlong, Marco Mielcarek, Marta Medeot, Ivana Gojo, B. Dougl...> ;Blood. 2017 Mar 9
142 citations
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
Shannon R. McCurdy, Yvette L. Kasamon, Christopher G. Kanakry, Javier Bolaños-Meade, Hua Ling Tsai, Margaret M. Showel, Jennifer A. Kanakry, Heather J. Symons, Ivana G...> ;Haematologica. 2017 Feb 1
Join now to see all

Journal Articles

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma
Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ, Gladstone DE, Perkins B, Link BK, Popplewell LL, Habermann TM, Herman JM, Matsui WH, Jones RJ, Ambinder RF., Blood, 2/16/2012

Abstracts/Posters

Solid Organ Transplant Rejection Associated with the Use of the Immunomodulatory Drugs (IMIDs)
Yvette L. Kasamon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures